13480-30-3

Basic information

• Product Name: 1-benzyl-4-(3'-pyridinyl)piperazine
• Synonyms: 1-benzyl-4-(3'-pyridinyl)piperazine
• CAS NO: 13480-30-3
• Molecular Weight: 253.347
• Mol File: 13480-30-3.mol
• Article Data: 6

Chemical Properties

• CAS DataBase Reference: 1-benzyl-4-(3'-pyridinyl)piperazine(CAS DataBase Reference)
• NIST Chemistry Reference: 1-benzyl-4-(3'-pyridinyl)piperazine(13480-30-3)
• EPA Substance Registry System: 1-benzyl-4-(3'-pyridinyl)piperazine(13480-30-3)

Safety Data

• Hazardous Substances Data: 13480-30-3(Hazardous Substances Data)

Upstream product

• 626-60-8 3-Chloropyridine 
• 2759-28-6 1-phenylmethylpiperazine 
• 223797-47-5 1-(pyridin-3-yl)-4-tert-butoxycarbonylpiperazine 
• 372-47-4 3-Fluoropyridine 
• 626-55-1 3-Bromopyridine 

Downstream Products

• 223794-26-1 1-methyl-4-(pyridin-3-yl)piperazine 
• 67980-77-2 1-(pyridin-3-yl)piperazine 

Relevant articles and documents

Sterically enriched bulky 1,3-bis(: N, N ′-aralkyl)benzimidazolium based Pd-PEPPSI complexes for Buchwald-Hartwig amination reactions

Pd-PEPPSI (palladium-pyridine enhanced pre-catalyst preparation stabilization and initiation) complexes are now emerging as well-defined catalysts for C-C and C-N bond formation. In connection with this, we prepared a family of six air and moisture stable

NOVEL COMPOUNDS

This invention relates to compounds of formula (I) their use as positive allosteric modulators of mGlu5 receptor activity, pharmaceutical compositions containing the same, and methods of using the same as agents for treatment and/or prevention of neurological and psychiatric disorders associated with glutamate dysfunction such as schizophrenia or cognitive decline such as dementia or cognitive impairment. A, B, Ar, R1, R2, R3 have meanings given in the description.

Modified aminoacids, pharmaceuticals containing these compounds and method for their production

The present invention relates to modified amino acids of general formula wherein A, Z, X, n, m, R, R2, R3, R4and R11are defined as in claims 1 to 5, their tautomers, their diastereomers, their enantiomers, the mixtures thereof and the salts thereof, particularly the physiologically acceptable salts thereof with inorganic or organic acids or bases, pharmaceutical compositions containing these compounds, the use thereof and processes for preparing them as well as their use for the production and purification of antibodies and as labelled compounds in RIA- and ELISA assays and as diagnostic or analytical aids in neurotransmitter research.